Ersodetug - Rezolute
Alternative Names: RZ-358; X 358; XOMA 247; XOMA 358; XPA.15.247Latest Information Update: 08 Aug 2024
At a glance
- Originator XOMA
- Developer Rezolute; XOMA
- Class Antihypoglycaemics; Monoclonal antibodies
- Mechanism of Action Insulin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Congenital hyperinsulinism
- Phase II Hypoglycaemia
Most Recent Events
- 05 Aug 2024 US FDA approves IND application for ersodetug in hypoglycemia due to tumor hyperinsulinism
- 05 Aug 2024 Rezolute plans a phase III registrational trial for Hypoglycemia in USA in the first half of 2025
- 16 May 2024 Pharmacodynamics data from a preclinical trial in Congenital Hyperinsulinism released by Rezolute